Elderly Cancer Patients Receiving Chemotherapy Benefit from First‐Cycle Pegfilgrastim by Balducci, Lodovico, Al‐Halawani, Hafez, Charu, Veena, Tam, Jennifer, Shahin, Seta, Dreiling, Lyndah, Ershler, William B.

Get full text

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 stu... by Kim, Sung-Bae, Ciruelos, Eva, Loi, Sherene, Knott, Adam, Agajanian, Richy, Ahmad, Rizvana, Aogi, Kenjiro, Arpornwirat, Wichit, Assersohn, Laura, Audeh, William, Bartoli, Maria Alejandra, Batista Lopez, Norberto, Bianconi, María, Birhiray, Ruemu, Blackwell, Kimberly, Blanchard, Rita, Blanchet, Paulette, Bower, Barbara, Brezden-Masley, Christine, Brufsky, Adam, Calvo, Lourdes, Campone, Mario, Castro, Hugo, Charu, Veena, Clemens, Michael, Coudert, Bruno, Cronemberger, Eduardo, Cubero, Daniel, Davidson, Neville, Del Pilar, Maria, Ellerton, John A., Fehrenbacher, Louis, Ferrero, Jean-Marc, Flynn, Patrick J., Foszczynska-Kloda, Malgorzata, Fujii, Hirofumi, Gallagher, Chris, Gotovkin, Eugeny, Green, Nathan, Grincuka, Elza, Hansen, Vincent, Hargis, Jeffrey, Hegg, Roberto, Hendricks, Carolyn, Hermann, Robert, Horiguchi, Jun, Hornedo Muguiro, Javier, Iwata, Dr Hiroji, Jendiroba, Davi, Jochim, Rosa, Jones, Alison, Karwal, Mark, Kashiwaba, Masahiro, Kato, Giraldo, Kellokumpu-Lehtinen, Pirkko, Kirsch, Andreas, Kotliar, Mauricio, Kümmel, Sherko, Kuroi, Katsumasa, Latini, Luciano, Marmé, Alexander, Martinez, Gloria, Matwiejuk, Mario, Merculov, Vladimir, Michaelson, Richard, Miguel, Luis, Montemurro, Filippo, Moura, Rodrigo, Mueller, Volkmar, Neidhart, Jeff, Nishimura, Reiki, Ogata, Haruki, Otero Reye, Douglas, Patel, Ravi, Patel, Taral, Pinczowski, Helio, Price, Paola Edith, Pyrhoenen, Seppo, Ribelles, Nuria, Sanchez-Rovira, Pedro, Schumacher, Claudia, Senecal, Frank, Simoncini, Edda, Sirisinha, Thitiya, Soria, Tania, Srimuninnimit, Vichien, Staroslawska, Elzbieta, Taguchi, Julie, Takeda, Koji, Tellez-Trevilla, Gabriel, Ueno, Takayuki, Varela, Mirta, Wang, Xiaojia, Wang, Liwei, Watanabe, Junichiro, Wesenberg, Birgitta, Wong, Zee Wan, Yardley, Denise, Yeo, Winnie, Youn Oh, Do

Get full text

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials by Lipton, Allan, Fizazi, Karim, Stopeck, Alison T, Henry, David H, Brown, Janet E, Yardley, Denise A, Richardson, Gary E, Siena, Salvatore, Maroto, Pablo, Clemens, Michael, Bilynskyy, Boris, Charu, Veena, Beuzeboc, Philippe, Rader, Michael, Viniegra, Maria, Saad, Fred, Ke, Chunlei, Braun, Ada, Jun, Susie

Get full text

Phase 3b UPFRONT Study: Safety and Efficacy of Weekly Bortezomib Maintenance Therapy After Bortezomib-Based Induction Regimens In Elderly, Newly Diagnosed Multiple Myeloma Patients by Niesvizky, Ruben, Flinn, Ian W., Rifkin, Robert M., Gabrail, Nashat Y, Charu, Veena, Clowney, Billy, Essell, James, Gaffar, Yousuf A, Warr, Thomas A., Neuwirth, Rachel, Corzo, Deyanira, Reeves, James A

Get full text

Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: Results of a phase III... by EISENBERG, Peter, FIGUEROA-VADILLO, Jazmin, ZAMORA, Rosalio, CHARU, Veena, HAJDENBERG, Julio, CARTMELL, Alan, MACCIOCCHI, Alberto, GRUNBERG, Steven

Get full text

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer... by Wakelee, Heather, Lee, Se-Hoon, Dooms, Christophe, Majem, Margarita, Novello, Silvia, Arunachalam, Ashwini, Keller, Steven M, Gao, Shugeng, Afanasyev, Sergey, Ahmed, Samreen, Alekshun, Todd, Alves, Gustavo, Anderson, Ian, Arkhipov, Alexander, Arora, Arvind, Berceanu-Ion, Radu, Bernabe Caro, Reyes, Bondarenko, Igor, Brocca, Carlos, Bryl, Maciej, Carcereny, Enric, Chaft, Jamie, Chaves, Fabio, Chen, Jun, Chiang, Chi-Lu, Ciurescu, Ioana, Coetzee, Corlia, Collins, Dearbhaile, Costas, Kimberly, Costin, Dan, Cronemberger, Eduardo Henrique, de Paiva Junior, Tadeu, Delmonte, Angelo, Demedts, Ingel, Dooms, Christophe, Dutra, Carolina, Ernani, Vinicius, Faehling, Martin, Ferrara, Roberto, Frohling, Klaus-Peter, Furqan, Muhammad, Gianni, Luca, Gilli, Marina, Goranov, Bojidar, Guarino, Michael, Halmos, Balazs, Ikeda, Norihiko, Intagliata, Salvatore, Jain, Kirti, Karaseva, Nina, Kaywin, Paul, Keresztes, Roger, Kolesnik, Oleksii, Kristedja, Timothy, Levenko, Oleh, Li, Shanqing, Liao, Bin-Chi, Lou, Yan Yan, Luft, Alexander, Ma, Shaohua, Majem Tarruella, Margarita, Makles, Krytsyna, Martinengo, Gaston, Martinez Marti, Alex, Matias, Danielli, Mazieres, Julien, Molina, Julian, Muto, Satoshi, Nadal Alforja, Ernest, Nesterova, Alfiya, Novello, Silvia, O'Brien, Mary, Ogliari, Francesca, Pastor, Andrea, Pollock, Theodore, Reinacher-Schick, Anke, Ritgen, Mathias, Ruff, Paul, Saji, Hisashi, Sardenberg, Rodrigo, Scheusan, Roxana, Serke, Monika, Shio, Yutaka, Siegel, Robert, Sokur, Iryna, Stencel, Katarzyna, Sugio, Kenji, Suzuki, Hiroyuki, Takamochi, Kazuya, Tan, Lijie, Tatangelo, Marcelo, Thiberville, Luc, Tsai, Chen-Liang, Ungureanu, Andrei, Vansteenkiste, Johan, Wang, Wenxiang, Wirtz, Hubert, Wong, Mark, Yang, Yue, Zhang, Lanjun

Get full text

Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib by Manda, Sudhir, Yimer, Habte A., Noga, Stephen J., Girnius, Saulius, Yasenchak, Christopher A., Charu, Veena, Lyons, Roger, Aiello, Jack, Bogard, Kimberly, Ferrari, Renda H., Cherepanov, Dasha, Demers, Brittany, Lu, Vickie, Whidden, Presley, Kambhampati, Suman, Birhiray, Ruemu E., Jhangiani, Haresh S., Boccia, Ralph, Rifkin, Robert M.

Get full text

A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma by Berenson, James R., Yellin, Ori, Shamasunder, Hesaraghatta K., Chen, Chien-Shing, Charu, Veena, Woliver, Thomas B., Sanani, Shamel, Schlutz, Michael, Nassir, Youram, Swift, Regina A., Andreu-Vieyra, Claudia, Vescio, Robert

Get full text

Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemothe... by Boccia, Ralph V., Gordan, Lucio N., Clark, Gemma, Howell, Julian D., Grunberg, Steven M.

Get full text

Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia by Hernandez, Enrique, Ganly, Peter, Charu, Veena, DiBenedetto, Joseph, Tomita, Dianne, Lillie, Tom, Taylor, Kerry

Get full text

Randomized Comparison of Epoetin Alfa (40,000 U Weekly) and Darbepoetin Alfa (200 μg Every 2 Weeks) in Anemic Patients with Cancer Receiving Chemotherapy by Waltzman, Roger, Croot, Christopher, Justice, Glen R., Fesen, Mark R., Charu, Veena, Williams, Denise

Get full text

Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with ran... by Glaspy, John A, Charu, Veena, Luo, Donghan, Moyo, Victor, Kamin, Marc, Wilhelm, Francois E

Get full text

A Randomized Comparison of Every‐2‐Week Darbepoetin Alfa and Weekly Epoetin Alfa for the Treatment of Chemotherapy‐Induced Anemia in Patients With Breast, Lung, or Gynecologic Canc... by Schwartzberg, Lee S., Yee, Lorrin K., Senecal, Frank M., Charu, Veena, Tomita, Dianne, Wallace, Joel, Rossi, Greg

Get full text

Patient-Reported Quality of Life (QoL) in Elderly, Newly Diagnosed Multiple Myeloma (MM) Patients Receiving Bortezomib-Based Combinations: Results From All Randomized Patients in t... by Niesvizky, Ruben, Flinn, Ian W., Rifkin, Robert, Gabrail, Nashat, Charu, Veena, Clowney, Billy, Gaffar, Yousuf, Warr, Thomas A., Neuwirth, Rachel, Huang, Hui, Choi, Sanggyu, Corzo, Deyanira

Get full text

Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results From All Randomized Patients in the Community-Based, Phase... by Niesvizky, Ruben, Flinn, Ian W., Rifkin, Robert, Gabrail, Nashat, Charu, Veena, Clowney, Billy, Essell, James, Gaffar, Yousuf, Warr, Thomas A., Neuwirth, Rachel, Corzo, Deyanira, Reeves, James

Get full text

Efficacy and Safety of Every‐2‐Week Darbepoetin Alfa in Patients with Anemia of Cancer: A Controlled, Randomized, Open‐Label Phase II Trial by Charu, Veena, Belani, Chandra P., Gill, Ahmad N., Bhatt, Mukesh, Tomita, Dianne, Rossi, Greg, Ben‐Jacob, Ali

Get full text

Erythroid Response to Epoetin alfa (EPO) 120,000 Units (U) Every Three Weeks (Q3W) Initiated Early or at a Standard Threshold in Chemotherapy-Induced Anemia (CIA) by Charu, Veena, Moyo, Victor, Luo, Donghan, Wilhelm, Francois E.

Get full text

Early vs Standard Intervention with an Extended Epoetin alfa (EPO) Dose Regimen of 120,000 Units (U) Every 3 Weeks (Q3W) in Chemotherapy (CT)-Induced Anemia: Results for Elderly vs... by Charu, Veena, Moyo, Victor, Luo, Donghan, Wilhelm, Francois E.

Get full text

TROPICS 1: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Tenecteplase for Restoration of Function in Central Venous Catheters by Gabrail, Nashat, Sandler, Eric, Charu, Veena, Anas, Nick, Lim, Eduardo, Blaney, Martha, Ashby, Mark, Gillespie, Barbara S, Begelman, Susan M

Get full text

Initiation of Epoetin-oc Therapy at a Starting Dose of 120,000 Units Once Every 3 Weeks in Patients With Cancer Receiving Chemotherapy : An Open-Label, Multicenter Study With Rando... by GLASPY, John A, CHARU, Veena, LUO, Donghan, MOYO, Victor, KAMIN, Marc, WILHELM, Francois E

Get full text